
Depending on dose, firmonertinib shrank tumors in 43% to 68% of patients as a first treatment for EGFR PACC-mutant lung cancer in the phase 1b FURTHER trial.
For Lung Cancer Awareness Month, here’s a round-up of the latest news and updates in this disease space.
For Lung Cancer Awareness Month, here’s a round-up of the latest news and updates in this disease space:






